Intellia Therapeutics shows positive clinical data on nex-z in Phase 1 trial for ATTR amyloidosis.

From GlobeNewswire: 2024-11-16 10:16:00

Intellia Therapeutics announced positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) in patients with ATTR amyloidosis, showing rapid, deep, and durable reduction in serum TTR levels. This reduction led to disease stabilization or improvement in ATTR-CM patients and stability or improvement in neuropathy in ATTRv-PN patients. The data was presented at the AHA Scientific Sessions and published in the New England Journal of Medicine. Nex-z demonstrated a favorable safety and tolerability profile, supporting its potential as a one-time treatment for ATTR amyloidosis. Further details will be discussed in an investor webcast on November 16.



Read more at GlobeNewswire: Intellia Announces First Clinical Evidence from Ongoing